SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-040412
Filing Date
2021-08-05
Accepted
2021-08-05 08:01:42
Documents
14
Period of Report
2021-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea145229-8k_protara.htm   iXBRL 8-K 27991
2 PRESS RELEASE DATED AUGUST 5, 2021, ISSUED BY THE REGISTRANT ea145229ex99-1_protara.htm EX-99.1 75665
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2616
  Complete submission text file 0001213900-21-040412.txt   295004

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE tara-20210805.xsd EX-101.SCH 3027
5 XBRL LABEL FILE tara-20210805_lab.xml EX-101.LAB 34915
6 XBRL PRESENTATION FILE tara-20210805_pre.xml EX-101.PRE 22790
7 EXTRACTED XBRL INSTANCE DOCUMENT ea145229-8k_protara_htm.xml XML 3762
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

IRS No.: 204580525 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36694 | Film No.: 211146404
SIC: 2836 Biological Products, (No Diagnostic Substances)